BlackRock, Inc. 13D and 13G filings for Protagonist Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-05 1:23 pm Sale | 2024-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 9,884,617 16.600% | -779,078 (-7.31%) | Filing |
| 2024-08-07 4:10 pm Purchase | 2024-07-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 10,663,695 18.200% | 5,119,793 (+92.35%) | Filing |
| 2024-01-24 2:27 pm Purchase | 2023-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 5,543,902 9.600% | 1,891,745 (+51.80%) | Filing |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 3,652,157 7.400% | 370,521 (+11.29%) | Filing |
| 2022-02-02 7:11 pm Purchase | 2021-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 3,281,636 6.900% | 689,925 (+26.62%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 2,591,711 6.200% | 935,470 (+56.48%) | Filing |
| 2020-06-09 4:32 pm Purchase | 2020-05-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 1,656,241 4.800% | 94,284 (+6.04%) | Filing |